Read time: 6 minutes
Highlights
Small DNA changes that accumulate in our body cells over a lifetime (researchers call them somatic mutations, from the Greek soma meaning body) may set a hard upper boundary on human longevity, even if medicine solves almost every other cause of ageing.
- The Theoretical Ceiling: A new model estimates a median human lifespan of 146 to 194 years if somatic mutations were the only remaining driver of ageing.
- The Critical Bottlenecks: Neurons and heart muscle cells can’t readily replace themselves, making the brain and heart the most important longevity constraints.
- The Regenerative Surprise: The liver could remain functional for tens of thousands of years in the model because it can continually replace damaged cells.
- The Reality Check: The study doesn’t predict that people will soon live to 194. It instead offers a theoretical upper bound under extraordinary assumptions.
- The Food Opportunity: Food and beverage leaders should focus on credible healthspan platforms supporting cognitive and cardiovascular health, not inflated immortality claims.
Could humans live to 194 years?
That’s the question now circulating after a remarkable new paper on cell mutations and aging. The researchers call these changes somatic mutations, from the Greek word soma meaning body, but you can think of them simply as the small DNA changes that accumulate in our body cells over a lifetime. The answer is both exciting and sobering!
Researchers from Skoltech and the Artificial Intelligence Research Institute have built a mathematical model asking what human longevity might look like if we eliminated almost every other driver of ageing.
Their conclusion is striking. If somatic mutations were the only remaining source of biological decline, median human lifespan could reach between 146 and 194 years. Maximum lifespan could range from 210 to 557 years, depending on how different organs age and fail.
But here’s the problem. This isn’t a prediction that people will soon be celebrating their 194th birthdays. It’s a theoretical boundary. It’s a way of asking what might remain after medical science has solved almost everything else.
The study, “Somatic mutations impose an entropic upper bound on human lifespan”, was published in npj Aging on 25 June 2026 by Efimov, Fedotov, Malaev and colleagues.
It gives us a powerful new way to think about longevity. More importantly, it offers a clear strategic signal for the food and beverage industry.
The mutations written into every life
So what are these mutations, exactly? Somatic mutations are small changes in DNA that occur in the cells of our bodies. They aren’t inherited through sperm or eggs. They happen in ordinary body cells throughout life.
Some arise during cell division. Others result from imperfect DNA repair. Some are associated with exposures such as tobacco smoke or ultraviolet light. And some simply occur because biological systems aren’t perfectly error-free.
Once a mutation has become fixed in a cell’s genome, the body generally can’t go back and restore the original sequence. The cell may continue functioning. It may die. It may reproduce and pass that mutation to its daughter cells. Or, in some cases, the mutation may contribute to disease.
Jordan Weiss of NYU Langone Health told Medical News Today that a person in their 80s carries thousands of somatic mutations in a typical cell. Over decades, this accumulated damage can gradually reduce cellular performance and, in some cases, contribute to cancer.
That’s a sobering thought. Every one of us is carrying a growing record of biological history inside our cells.
The important point is that somatic mutations aren’t the same as inherited genetic variants. They’re part of what makes each tissue a mosaic of slightly different cells. The older we become, the more changes accumulate across that mosaic.
What the researchers modelled
The researchers used an incremental mathematical model of population survival.
First, they modelled a hypothetical non-ageing population. In this scenario, mortality risk remained constant rather than increasing with age. Under their selected assumptions, median lifespan reached 1,759 years and the maximum reached 29,221 years.
Today that number sounds absurd. It’s meant to!
It shows what happens when the familiar biological processes of ageing are removed from the equation. It isn’t a currently realistic human forecast. It’s a baseline. The researchers then added somatic mutation-driven cell death. They treated the body as a reliability system made up of critical organs. Think of it like a chain. If one essential link breaks, the whole chain can fail.
Just think about this for a minute. A human body isn’t like a fleet of spare parts where every damaged component can be swapped out indefinitely. Some tissues have impressive regenerative capacity. Others don’t. The model included the brain, heart, liver and respiratory epithelium. It also considered differences in mutation rates, cell death, regeneration and organ failure thresholds.
When somatic mutations were added back into the idealised system, the lifespan estimates fell dramatically.
Median lifespan landed between 146 and 194 years. Maximum lifespan fell to between 210 and 557 years, depending on the assumed relationship between organ failure times.
Under an independence assumption, the multi-organ model produced a median lifespan of approximately 156 years and a maximum of about 470 years.
That’s still extraordinary. But it’s nowhere near immortality.
Why the brain and heart matter most
The most fascinating insight is the asymmetry between organs.
Neurons in the brain and cardiomyocytes in the heart are largely post-mitotic cells. In simple terms, they don’t routinely divide and replace themselves in the way many other cells do. If a liver cell is lost, another cell can often step in. If a neuron or heart muscle cell is lost, the replacement process is far more limited.
The model estimates a median lifespan of 194 years and a maximum of 557 years when neuron-driven failure is considered in isolation. For cardiomyocytes, the estimates reach a median of 208 years and a maximum of 868 years.
The brain therefore becomes a critical longevity bottleneck. The heart becomes another. This doesn’t mean the brain or heart will suddenly fail at a specific age. It means that, in a hypothetical world without the usual diseases and ageing processes, the gradual loss of irreplaceable cells could eventually limit survival.
The study’s brain model is especially relevant to healthspan. Biological survival isn’t enough. The researchers considered a cognitive threshold, recognising that a person might remain technically alive while losing the ability to live independently.
That distinction matters enormously.
I’m far more interested in the years of clear thinking, mobility, independence and social connection than in simply adding numbers to a lifespan chart.
My earlier articles on rewriting the biological clock and whether ageing is a disease to be cured explore other potential routes through this challenge. This new research adds an important warning. Repairing proteins, restoring cellular identity or clearing damaged cells may not be enough if critical tissues can’t be safely renewed.
The liver delivers an amazing surprise
The liver tells a completely different story.
Liver cells can divide and replace damaged or lost cells. The researchers found that this regenerative capacity could effectively neutralise mutation-driven decline for extremely long periods. In one model, the liver remained functional for more than 100,000 years of simulation. Even without additional stem cell support, liver function extended beyond 37,000 years.
Obviously, nobody is suggesting that a human liver will function for 100,000 years. The model deliberately removes many biological realities, including chronic inflammation, cancer, immune decline, clonal expansion and interactions between ageing mechanisms.
Still, the contrast is powerful.
The liver can dilute or replace damaged cells. The brain and heart can’t do so as easily. This is why ageing isn’t uniform across the body. It’s a systems problem shaped by the renewal capacity of each tissue.
The study’s biggest limitation
We need to be very clear here. This is mathematical modelling, not a clinical trial or a human longevity intervention.
The model assumes that almost every other hallmark of ageing has been eliminated. That includes cardiovascular disease, cancer, infections, mitochondrial decline, telomere attrition, protein damage and other causes of age-related mortality.
It also assumes no accidents, wars, environmental disasters or other external causes of death. The researchers modelled only selected organs and used assumptions about how those organs interact. The paper also excludes several important mechanisms. Mutations may impair cells without immediately killing them. Mutant cell populations may expand and take over tissue. Immune surveillance may fail. One ageing process may accelerate another.
In real life, these feedback loops matter enormously.
The longest documented human life remains 122 years, achieved by Jeanne Calment. We’re a long way from even approaching the study’s theoretical median range.
The central conclusion isn’t that humans are about to live twice as long. It’s that somatic mutations appear to be a major but incomplete driver of ageing. If removing them only takes us from today’s median lifespan of around 79 years to somewhere near 156 years, other hallmarks must contribute at least as much to current mortality.
That’s a hugely important insight.
It means there are still many opportunities to improve healthspan before we reach any ultimate biological ceiling.
One influential counterpoint comes from David Sinclair and his colleagues at Harvard. Their information theory of aging suggests that cells may carry a backup copy of their original, youthful instructions, stored in the epigenetic software that switches genes on and off. When cells accumulate damage, that software becomes noisy, but the backup may remain intact. In lab experiments, researchers have restored youthful gene expression in damaged mouse tissues by briefly switching on a handful of reprogramming genes. If that backup can be reliably accessed in humans, it would soften this study’s conclusion. The npj Aging paper assumes mutation-driven damage is effectively permanent, which is what creates the hard 194-year ceiling. Sinclair’s theory suggests at least part of that damage could be corrected, potentially pushing the practical ceiling beyond what the model assumes. In other words, the ceiling may not be as solid as it first appears. Entropy is the tendency of systems to drift towards disorder over time, which is a neat way of describing how mutations accumulate. But if some of that disorder can be reversed, the hard limit this study describes could be pushed higher.
What this means for food and beverage leaders
So, what does a complex paper on cell mutation have to do with your product portfolio?
Everything!
The longevity economy is moving away from vague promises and towards measurable biological outcomes. Consumers will increasingly ask whether a product supports the systems that keep them healthy, functional and independent.
That creates four clear opportunities.
1. Build cognitive health platforms
The brain is one of the most important longevity bottlenecks in the model. Food and beverage companies should think beyond short-term energy and mood claims.
Cognitive health platforms could include products supporting adequate protein intake, vascular health, sleep quality, healthy inflammation levels and the gut-brain connection.
The opportunity isn’t to claim that a drink prevents neuronal mutations. That would be irresponsible. The opportunity is to support the conditions associated with better cognitive health across the life course.
2. Build cardiovascular health platforms
The heart is another critical bottleneck. That makes cardiovascular health one of the most valuable and credible foundations for longevity positioning.
Products can be designed around dietary patterns rich in fibre, legumes, nuts, whole grains, fruits, vegetables and healthy fats. There’s also growing opportunity in personalised nutrition that helps consumers manage metabolic risk, blood pressure and lipid profiles.
Again, the language matters. “Supports cardiovascular health” is very different from “extends your life by 20 years”.
3. Design for the healthspan economy
The future consumer won’t just want to live longer. They’ll want to remain active for longer.
That means product development should consider healthy ageing benefits across multiple life stages. Can the product support muscle maintenance? Does it help consumers eat enough protein? Can it improve convenience without sacrificing nutritional quality? Does it fit the needs of older adults who still want performance, travel, work and social connection?
This is where product longevity becomes strategically important. A strong platform shouldn’t be a short-lived trend. It should be able to evolve as the science, consumer expectations and regulatory environment change.
4. Make personalisation useful
The study reinforces that different tissues age differently. That supports a wider move towards personalisation.
People won’t all need identical nutrition strategies. Their age, activity, health status, genetics, microbiome, sleep and metabolic responses will shape what works best for them.
Personalisation doesn’t have to mean a futuristic laboratory in every kitchen. It could begin with better segmentation, smarter digital guidance, wearable data, targeted meal plans and products designed around specific health goals.
Through my FutureCUBED™ process, I help leaders connect emerging science with practical strategy. The key is to separate what’s genuinely actionable today from what belongs in a longer-term foresight scenario.
My conclusion
This study gives us an intriguing thought experiment.
It suggests that even if we cure most diseases and reverse many hallmarks of ageing, mutation-driven damage in irreplaceable cells may still impose a hard limit on human longevity.
But I don’t see that as a reason for pessimism.
I see it as a reason to focus. The highest-value longevity strategy today is still remarkably familiar. Don’t smoke. Move regularly. Eat a whole-food diet. Sleep well. Maintain social connection. Prevent disease wherever possible.
According to the commentators quoted by Medical News Today, these basics could add 10 to 20 healthy years, which is more than any anti-ageing intervention has delivered to date.
For food and beverage leaders, the lesson is direct. Don’t chase immortality claims. Build trusted healthspan platforms. Support the brain and heart. Use personalisation where it genuinely improves outcomes. And give consumers products that help them enjoy more healthy, functional years.
For the latest perspective, I also recommend my speaker articles on the 12 hallmarks of ageing and nutrition and precision longevity.
The question I’ll leave you with is this. If the future of longevity depends less on living forever and more on protecting the brain, heart and years of independence, how should your business change today?
To continue the conversation email me at tony@futuristforfood.com
